Patruni et al., 2023 - Google Patents
Immunotherapy in the management of esophagogastric cancer: A practical reviewPatruni et al., 2023
View PDF- Document ID
- 614289802983760029
- Author
- Patruni S
- Fayyaz F
- Bien J
- Phillip T
- King D
- Publication year
- Publication venue
- JCO Oncology Practice
External Links
Snippet
Recent data support incorporation of immune checkpoint inhibitors into the treatment armamentarium for esophageal, gastroesophageal junction, and gastric (esophagogastric) cancer. This practical review focuses on clinical trials that influenced US Food and Drug …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abida et al. | Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study | |
| Piper-Vallillo et al. | Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review | |
| Pishvaian et al. | Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumor program | |
| Broeckx et al. | Malignant peritoneal mesothelioma: a review | |
| Lennerz et al. | MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | |
| Telli et al. | Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation–associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105 | |
| Ignatiadis et al. | Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis | |
| Perez et al. | HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial | |
| Jänne et al. | Epidermal growth factor receptor mutations in non–small-cell lung cancer: Implications for treatment and tumor biology | |
| Allegra et al. | Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: A national cancer institute–national surgical adjuvant breast and bowel project collaborative study | |
| Black et al. | Variant histology in bladder cancer: diagnostic and clinical implications | |
| Zhai et al. | Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer | |
| Lan et al. | APOBEC3G expression is correlated with poor prognosis in colon carcinoma patients with hepatic metastasis | |
| Patruni et al. | Immunotherapy in the management of esophagogastric cancer: A practical review | |
| Xu et al. | Highly expressed Claudin18. 2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC) | |
| Oh et al. | Deep and durable response with combination CTLA-4 and PD-1 blockade in mismatch repair (MMR)-proficient endometrial cancer | |
| Van't Erve et al. | KRAS A146 mutations are associated with distinct clinical behavior in patients with colorectal liver metastases | |
| Ambrosini et al. | ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series | |
| Innocenti et al. | DNA mutational profiling in patients with colorectal cancer treated with standard of care reveals differences in outcome and racial distribution of mutations | |
| Yoshimura et al. | MET amplification and efficacy of nivolumab in patients with NSCLC | |
| Moy et al. | Defining and targeting Esophagogastric Cancer genomic subsets with patient-derived xenografts | |
| Shen et al. | Plasma mRNA as liquid biopsy predicts chemo-sensitivity in advanced gastric cancer patients | |
| McLean et al. | Immunotherapy in oncogene addicted non-small cell lung cancer | |
| Kim et al. | Insertion–deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab | |
| Zschäbitz et al. | Expression of nectin-4 in papillary renal cell carcinoma |